NCT00328198 2014-03-13Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaSanofiPhase 2 Completed86 enrolled 15 charts
NCT00800943 2008-12-03CRC005Chronic Lymphocytic Leukemia Research ConsortiumPhase 2 Unknown31 enrolled